...
search icon
halo-img

Halozyme Therapeutics Inc, Common Stock

HALO

NSQ

$56

+$0.14

(0.25%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.12B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
18.4967
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.19M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.29
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$33.15 L
$65.53 H
$56

About Halozyme Therapeutics Inc, Common Stock

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameHALOSectorS&P500
1-Week Return0.11%3.54%-0.58%
1-Month Return16.69%7.51%1.89%
3-Month Return10.98%-0.85%3.24%
6-Month Return0.96%-1.67%10.09%
1-Year Return62.74%5.2%22.09%
3-Year Return71.99%13.08%35.68%
5-Year Return188.36%44.4%83.47%
10-Year Return295.76%111.45%200.41%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue195.99M267.59M443.31M660.12M829.25M[{"date":"2019-12-31","value":23.63,"profit":true},{"date":"2020-12-31","value":32.27,"profit":true},{"date":"2021-12-31","value":53.46,"profit":true},{"date":"2022-12-31","value":79.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue45.55M43.37M81.41M139.30M192.36M[{"date":"2019-12-31","value":23.68,"profit":true},{"date":"2020-12-31","value":22.54,"profit":true},{"date":"2021-12-31","value":42.32,"profit":true},{"date":"2022-12-31","value":72.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit150.45M224.23M361.90M520.81M636.89M[{"date":"2019-12-31","value":23.62,"profit":true},{"date":"2020-12-31","value":35.21,"profit":true},{"date":"2021-12-31","value":56.82,"profit":true},{"date":"2022-12-31","value":81.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin76.76%83.79%81.64%78.90%76.80%[{"date":"2019-12-31","value":91.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.42,"profit":true},{"date":"2022-12-31","value":94.16,"profit":true},{"date":"2023-12-31","value":91.66,"profit":true}]
Operating Expenses218.06M79.97M86.00M253.28M299.32M[{"date":"2019-12-31","value":72.85,"profit":true},{"date":"2020-12-31","value":26.72,"profit":true},{"date":"2021-12-31","value":28.73,"profit":true},{"date":"2022-12-31","value":84.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(67.61M)144.25M275.90M267.53M337.57M[{"date":"2019-12-31","value":-20.03,"profit":false},{"date":"2020-12-31","value":42.73,"profit":true},{"date":"2021-12-31","value":81.73,"profit":true},{"date":"2022-12-31","value":79.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(16.27M)(35.33M)(34.91M)(35.56M)(8.01M)[{"date":"2019-12-31","value":-1626800000,"profit":false},{"date":"2020-12-31","value":-3533100000,"profit":false},{"date":"2021-12-31","value":-3491000000,"profit":false},{"date":"2022-12-31","value":-3556000000,"profit":false},{"date":"2023-12-31","value":-800700000,"profit":false}]
Pre-Tax Income(72.25M)129.30M248.52M248.92M348.33M[{"date":"2019-12-31","value":-20.74,"profit":false},{"date":"2020-12-31","value":37.12,"profit":true},{"date":"2021-12-31","value":71.35,"profit":true},{"date":"2022-12-31","value":71.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes(11.00K)217.00K(154.19M)46.79M66.73M[{"date":"2019-12-31","value":-0.02,"profit":false},{"date":"2020-12-31","value":0.33,"profit":true},{"date":"2021-12-31","value":-231.05,"profit":false},{"date":"2022-12-31","value":70.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(72.24M)129.09M402.71M202.13M281.59M[{"date":"2019-12-31","value":-17.94,"profit":false},{"date":"2020-12-31","value":32.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50.19,"profit":true},{"date":"2023-12-31","value":69.92,"profit":true}]
Income From Continuous Operations(72.24M)129.09M402.71M202.13M281.59M[{"date":"2019-12-31","value":-17.94,"profit":false},{"date":"2020-12-31","value":32.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50.19,"profit":true},{"date":"2023-12-31","value":69.92,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(72.24M)129.09M402.71M202.13M281.59M[{"date":"2019-12-31","value":-17.94,"profit":false},{"date":"2020-12-31","value":32.05,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":50.19,"profit":true},{"date":"2023-12-31","value":69.92,"profit":true}]
EPS (Diluted)(0.50)0.901.922.222.78[{"date":"2019-12-31","value":-17.99,"profit":false},{"date":"2020-12-31","value":32.37,"profit":true},{"date":"2021-12-31","value":69.06,"profit":true},{"date":"2022-12-31","value":79.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

HALO
Cash Ratio 6.12
Current Ratio 10.36
Quick Ratio 9.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HALO
ROA (LTM) 14.87%
ROE (LTM) 111.83%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HALO
Debt Ratio Lower is generally better. Negative is bad. 0.79
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.21

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HALO
Trailing PE 18.50
Forward PE 11.86
P/S (TTM) 7.50
P/B 15.67
Price/FCF 62
EV/R 8.37
EV/Ebitda 13.67
PEG NM

FAQs

What is Halozyme Therapeutics Inc share price today?

Halozyme Therapeutics Inc (HALO) share price today is $56

Can Indians buy Halozyme Therapeutics Inc shares?

Yes, Indians can buy shares of Halozyme Therapeutics Inc (HALO) on Vested. To buy Halozyme Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HALO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Halozyme Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Halozyme Therapeutics Inc (HALO) via the Vested app. You can start investing in Halozyme Therapeutics Inc (HALO) with a minimum investment of $1.

How to invest in Halozyme Therapeutics Inc shares from India?

You can invest in shares of Halozyme Therapeutics Inc (HALO) via Vested in three simple steps:

  • Click on Sign Up or Invest in HALO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Halozyme Therapeutics Inc shares
What is Halozyme Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Halozyme Therapeutics Inc (HALO) is $65.53. The 52-week low price of Halozyme Therapeutics Inc (HALO) is $33.15.

What is Halozyme Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Halozyme Therapeutics Inc (HALO) is 18.4967

What is Halozyme Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Halozyme Therapeutics Inc (HALO) is 15.67

What is the Market Cap of Halozyme Therapeutics Inc?

The market capitalization of Halozyme Therapeutics Inc (HALO) is $7.12B

What is Halozyme Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Halozyme Therapeutics Inc is HALO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top